EXSCIENTIA LTD announced that it has received $26 million in its series B round of funding on January 7, 2019. The transaction included participation from new investors Celgene Corporation (NasdaqGS:CELG), and GT Healthcare Capital Partners along with existing investor Evotec AG (XTRA:EVT) which invested $6 million.